title: Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles.
abstract: siRNA is currently the most widely studied form of RNAi, and it has promising therapeutic potential not just in cancer but also in other diseases such as autoimmune and infectious diseases. However, efficient delivery of siRNA to target cells is being limited by lack of an effective delivery system that ensures efficient transfection into cells while protecting the encapsulated siRNA from nuclease. We hypothesized that a hybrid nanoparticle system composed of human IgG and poloxamer-188, a stealth polymer, will efficiently deliver mutated KRAS siRNA to A549 cells, leading to an efficient knockdown of mutated siRNA while protecting the siRNA from serum nuclease. We also hypothesized that the nanoparticles will not elicit an immunostimulatory effect in murine macrophages and also avoid clearance by macrophages. These nanoparticles were found to efficiently deliver siRNA to the cytoplasm and nuclease of A549 cells in a controlled and sustained manner while avoiding recycling by endosomes. An effective knockdown of mutated KRAS was achieved, which subsequently led to an increased sensitivity to erlotinib. These nanoparticles successfully avoided uptake by murine macrophages and reduced immune responses normally associated with siRNA/nanoparticle therapy. These results demonstrate that the novel hybrid nanoparticles could potentially serve as a platform for efficient delivery of siRNA to cells for stable gene knockdown.
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, and ‡Division of Molecular Radiation Biology, Department of Radiation Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania 19107, United States.
authors.forename: A
authors.initials: A
authors.lastname: Lakshmikuttyamma
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: B
authors.initials: B
authors.lastname: Lu
authors.forename: A S
authors.initials: AS
authors.lastname: Undieh
authors.forename: S A
authors.initials: SA
authors.lastname: Shoyele
mesh_terms: D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D034741:RNA, Small Interfering / Q000737:chemistry* / Q000235:genetics*; D014162:Transfection / Q000379:methods*; D018631:ras Proteins / Q000235:genetics*
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
keywords: RNAi; gene knockdown; hybrid nanoparticles; lung cancer; mutated KRAS; nuclease